[JP Morgan] Bridge Biotherapeutics CEO James Jungkue Lee highlights potential breakthrough for idiopathic pulmonary fibrosis candidate '먹튀 없는 바카라 사이트877'

[by Kang, In Hyo] “At this year’s JP Morgan Healthcare Conference, four companies, including Bristol Myers Squibb (BMS), Puretech, Pliant Therapeutics, and our company, presented their treatment pipelines for idiopathic pulmonary 먹튀 없는 바카라 사이트 (IPF). Based only on the data presented, I believe our data is the best.”

In an interview with <THE BIO during the ‘2025 JP Morgan Healthcare Conference,’ the world’s largest pharmaceutical and biotechnology investment event, held in San Francisco, USA, on January 15th (local time), James Jungkue Lee, CEO of Bridge Biotherapeutics, stated, “Although the global phase 2 clinical trial for our Idiopathic Pulmonary Fibrosis treatment candidate, ‘먹튀 없는 바카라 사이트877 (development code name),’ is still ongoing, the combined data from the treatment and placebo groups, which remain ‘unblinded,’ appear to be the most promising.”

“먹튀 없는 바카라 사이트877 is now in the final stages of global phase 2 clinical trials, with top-line data expected in April,” Lee further explained. “At that point, we will analyze the data separately from the treatment and placebo groups to determine the extent of change in the primary efficacy evaluation parameter, ‘Forced Vital Capacity (FVC),’ specifically in the treatment group alone.”

먹튀 없는 바카라 사이트 described Bridge Biotherapeutics’ official invitation to present during the main session of the JP Morgan Healthcare Conference as an unexpected and “big surprise.” The interview took place before the main session presentation scheduled for January 16.

“Had the multinational pharmaceutical company Boehringer Ingelheim not discontinued 먹튀 없는 바카라 사이트877, we could have secured global exclusivity,” Lee emphasized. “The development of 먹튀 없는 바카라 사이트877 is about two years ahead of its three competitors. At this JP Morgan Healthcare Conference, we held partnering discussions with four of the 10 major global pharmaceutical companies, and when including another, we have explored technology transfer opportunities for 먹튀 없는 바카라 사이트877 with a total of five global major companies,” he further commented. “Nine of the top 10 global pharmaceutical companies have expressed interest in 먹튀 없는 바카라 사이트877, and if the top-line results meet expectations, a global technology transfer could take place as early as June.”

“I was surprised to see seven attendees from the company we met with last Monday,” Lee particularly noted. “Their delegation included not only R&D staff but also commercialization staff, which clearly demonstrated the strong interest and significant demand from global companies for a large-scale technology transfer of 먹튀 없는 바카라 사이트877.”

In July 2019, Bridge Biotherapeutics entered into a technology transfer agreement with Boehringer Ingelheim for 먹튀 없는 바카라 사이트877 during its phase 1 clinical trial, valued at around KRW 1.5 trillion (approximately USD 1 billion). At the time, this represented the largest technology transfer deal for a single compound. In the same year, Bridge Biotherapeutics was listed on the KOSDAQ market, receiving KRW 60 billion in upfront payments and short-terms milestone fees (stage-by-stage technology fees) as part of the agreement. However, in 2020, Boehringer Ingelheim returned the rights of 먹튀 없는 바카라 사이트877 to Bridge Biotherapeutics, citing concerns over potential toxicity.

“I am deeply moved that the phase 2 clinical data is progressing well and that it has enabled us to present at the main session of the JP Morgan Healthcare Conference,” Lee remarked. “It was challenging when 먹튀 없는 바카라 사이트877, which had achieved a successful global technology export, was returned after just one year. However, our company’s position has strengthened since then, as the market for idiopathic pulmonary fibrosis treatments has grown and competitors have faced setbacks in their clinical trials.”

He went on to say, “먹튀 없는 바카라 사이트877 has demonstrated excellent safety, and if its efficacy meets expectations, it can be regarded as a true ‘treatment’,” and added, “To secure the best possible deal conditions, full-scale negotiations are expected to begin after the release of top-line data. We are committed to making the global technology transfer of 먹튀 없는 바카라 사이트877 a success once again.”

Lee concluded by stating, “Along with the global technology transfer of 먹튀 없는 바카라 사이트877, which is nearing the completion of phase 2 clinical trials this year, we plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the fourth quarter for phase 2 clinical trials of ‘먹튀 없는 바카라 사이트301,’ another pulmonary fibrosis drug candidate.” He added, “We also aim to finalize the phase 1 dose-escalation trial for ‘먹튀 없는 바카라 사이트207,’ a lung cancer treatment candidate, and proceed to phase 1b clinical trials.”